We demonstrate that combinations of 4-hydroxytamoxifen at a low inhibitory concentration and any isothiocyanate at concentrations lower than their IC50 values inhibit cell proliferation of ER-positive human breast cancer cells more efficiently than any compound used alone. This evidence concerns the gene ESR1 and breast carcinoma.